Modulating inhibitors of transthyretin fibrillogenesis via sulfation: Polychlorinated biphenyl sulfates as models

Chemico-Biological Interactions

Volumn 228, Issue , 2015, Pages 1-8

  Grimm, Fabian A ^a   Lehmler, Hans Joachim ^a   He, Xianran ^a   Robertson, Larry W ^a   Duffel, Michael W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Amyloidosis; PCBs; Polychlorinated biphenyls; Sulfation; Transthyretin; TTR

Indexed keywords

2,3',4' TRICHLORO 4' SULFOOXY BIPHENYL 33 SULFATE; 2,3',5 TRICHLORO 4' SULFOOXY BIPHENYL 26 SULFATE; 2,4' DICHLORO 4 SULFOOXY BIPHENYL 8 SULFATE; 3,3' DICHLORO 4 SULFOOXY BIPHENYL 11 SULFATE; 3,3' DICHLOROBIPHENYL; 3,3' DICHLOROBIPHENYL 4 OL; 3,3',4',5 TETRACHLOROBIPHENYL 4 OL; 4 CHLORO 3' SULFOOXY BIPHENYL 3 SULFATE; 4 CHLORO 4' SULFOOXY BIPHENYL 3 SULFATE; 4' CHLOROBIPHENYL 3 OL; 4' CHLOROBIPHENYL 4 OL; BENZOXAZOLE DERIVATIVE; DIBENZOFURAN DERIVATIVE; FLUFENAMIC ACID; POLYCHLORINATED BIPHENYL DERIVATIVE; POLYCHLORINATED BIPHENYL SULFATE DERIVATIVE; PREALBUMIN; TETRACHLOROBIPHENYL; THYROXINE; UNCLASSIFIED DRUG; AMYLOID; SULFATE;

AMYLOIDOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG STRUCTURE; HYDROPHOBIC INTERACTION; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR INTERACTION; STATIC ELECTRICITY; SULFATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION;

AMYLOID; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PREALBUMIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATES;

EID: 84922275796     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.01.002     Document Type: Article

References (41)

1. J.N. Buxbaum, and N. Reixach Transthyretin: the servant of many masters Cell. Mol. Life Sci. 66 2009 3095 3101
2. D.J. Selkoe Folding proteins in fatal ways Nature 426 2003 900 904
3. F. Schneider, P. Hammarstrom, and J.W. Kelly Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins Protein Sci. 10 2001 1606 1613
4. Y. Sekijima, T. Tokuda, F. Kametani, K. Tanaka, K. Maruyama, and S. Ikeda Serum transthyretin monomer in patients with familial amyloid polyneuropathy Amyloid 8 2001 257 262
5. S. Connelly, S. Choi, S.M. Johnson, J.W. Kelly, and I.A. Wilson Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses Curr. Opin. Struct. Biol. 20 2010 54 62
6. A.R. Hurshman Babbes, E.T. Powers, and J.W. Kelly Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis Biochemistry 47 2008 6969 6984
7. H.A. Lashuel, D. Hartley, B.M. Petre, T. Walz, and P.T. Lansbury Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations Nature 418 2002 291
8. P. Westermark, K. Sletten, B. Johansson, and G.G. Cornwell 3rd Fibril in senile systemic amyloidosis is derived from normal transthyretin Proc. Natl. Acad. Sci. USA 87 1990 2843 2845
9. C. Rapezzi, C.C. Quarta, L. Riva, S. Longhi, I. Gallelli, M. Lorenzini, P. Ciliberti, E. Biagini, F. Salvi, and A. Branzi Transthyretin-related amyloidoses and the heart: a clinical overview Nat. Rev. Cardiol. 7 2010 398 408
10. T. Coelho Familial amyloid polyneuropathy: new developments in genetics and treatment Curr. Opin. Neurol. 9 1996 355 359
11. D.R. Jacobson, R.D. Pastore, R. Yaghoubian, I. Kane, G. Gallo, F.S. Buck, and J.N. Buxbaum Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans N. Engl. J. Med. 336 1997 466 473
12. M. Ueda, and Y. Ando Recent advances in transthyretin amyloidosis therapy Transl. Neurodegener. 3 2014 19
13. G. Merlini, and V. Bellotti Molecular mechanisms of amyloidosis N. Engl. J. Med. 349 2003 583 596
14. C.C. Blake, M.J. Geisow, S.J. Oatley, B. Rerat, and C. Rerat Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A J. Mol. Biol. 121 1978 339 356
15. A. Wojtczak, V. Cody, J.R. Luft, and W. Pangborn Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3′,5′-dinitro-N-acetyl-l-thyronine at 2.2 A resolution Acta Crystallogr. D Biol. Crystallogr. 52 1996 758 765
16. R.N. Ferguson, H. Edelhoch, H.A. Saroff, J. Robbins, and H.J. Cahnmann Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid Biochemistry 14 1975 282 289
17. T. Klabunde, H.M. Petrassi, V.B. Oza, P. Raman, J.W. Kelly, and J.C. Sacchettini Rational design of potent human transthyretin amyloid disease inhibitors Nat. Struct. Biol. 7 2000 312 321
18. H.M. Petrassi, S.M. Johnson, H.E. Purkey, K.P. Chiang, T. Walkup, X. Jiang, E.T. Powers, and J.W. Kelly Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state J. Am. Chem. Soc. 127 2005 6662 6671
19. H.E. Purkey, S.K. Palaninathan, K.C. Kent, C. Smith, S.H. Safe, J.C. Sacchettini, and J.W. Kelly Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity Chem. Biol. 11 2004 1719 1728
20. D. Tomar, T. Khan, R.R. Singh, S. Mishra, S. Gupta, A. Surolia, and D.M. Salunke Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites PLoS One 7 2012 e43522
21. N. Ferreira, A. Pereira-Henriques, A. Attar, F.G. Klarner, T. Schrader, G. Bitan, L. Gales, M.J. Saraiva, and M.R. Almeida Molecular tweezers targeting transthyretin amyloidosis Neurotherapeutics 11 2014 450 461
22. T. Yokoyama, Y. Kosaka, and M. Mizuguchi Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin J. Med. Chem. 57 2014 8928 8935
23. E.Y. Cotrina, M. Pinto, L. Bosch, M. Vila, D. Blasi, J. Quintana, N.B. Centeno, G. Arsequell, A. Planas, and G. Valencia Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation J. Med. Chem. 56 2013 9110 9121
24. T. Coelho, L.F. Maia, A.M. da Silva, M.W. Cruz, V. Plante-Bordeneuve, O.B. Suhr, I. Conceicao, H.H. Schmidt, P. Trigo, J.W. Kelly, R. Labaudiniere, J. Chan, J. Packman, and D.R. Grogan Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy J. Neurol. 260 2013 2802 2814
25. G. Merlini, V. Plante-Bordeneuve, D.P. Judge, H. Schmidt, L. Obici, S. Perlini, J. Packman, T. Tripp, and D.R. Grogan Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis J. Cardiovasc. Transl. Res. 6 2013 1011 1020
26. J.L. Berk, O.B. Suhr, L. Obici, Y. Sekijima, S.R. Zeldenrust, T. Yamashita, M.A. Heneghan, P.D. Gorevic, W.J. Litchy, J.F. Wiesman, E. Nordh, M. Corato, A. Lozza, A. Cortese, J. Robinson-Papp, T. Colton, D.V. Rybin, A.B. Bisbee, Y. Ando, S. Ikeda, D.C. Seldin, G. Merlini, M. Skinner, J.W. Kelly, and P.J. Dyck Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial JAMA 310 2013 2658 2667
27. T. Coelho, D. Adams, A. Silva, P. Lozeron, P.N. Hawkins, T. Mant, J. Perez, J. Chiesa, S. Warrington, E. Tranter, M. Munisamy, R. Falzone, J. Harrop, J. Cehelsky, B.R. Bettencourt, M. Geissler, J.S. Butler, A. Sehgal, R.E. Meyers, Q. Chen, T. Borland, R.M. Hutabarat, V.A. Clausen, R. Alvarez, K. Fitzgerald, C. Gamba-Vitalo, S.V. Nochur, A.K. Vaishnaw, D.W. Sah, J.A. Gollob, and O.B. Suhr Safety and efficacy of RNAi therapy for transthyretin amyloidosis N. Engl. J. Med. 369 2013 819 829
28. S. Crunkhorn Trial watch: Success in amyloidosis trials supports potential of systemic RNAi Nat. Rev. Drug Discov. 12 2013 818
29. Y. Hayashi, Y. Mori, T. Higashi, K. Motoyama, H. Jono, D.W. Sah, Y. Ando, and H. Arima Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/alpha-cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy Amyloid 19 Suppl. 1 2012 47 49
30. F.A. Grimm, H.J. Lehmler, X. He, L.W. Robertson, and M.W. Duffel Sulfated metabolites of polychlorinated biphenyls are high-affinity ligands for the thyroid hormone transport protein transthyretin Environ. Health Perspect. 121 2013 657 662
31. H.J. Lehmler, and L.W. Robertson Synthesis of hydroxylated PCB metabolites with the Suzuki-coupling Chemosphere 45 2001 1119 1127
32. X. Li, S. Parkin, M.W. Duffel, L.W. Robertson, and H.J. Lehmler An efficient approach to sulfate metabolites of polychlorinated biphenyls Environ. Int. 36 2010 843 848
33. H.J. Lehmler, and L.W. Robertson Synthesis of polychlorinated biphenyls (PCBs) using the Suzuki-coupling Chemosphere 45 2001 137 143
34. Z. Lai, W. Colon, and J.W. Kelly The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid Biochemistry 35 1996 6470 6482
35. S.L. Adamski-Werner, S.K. Palaninathan, J.C. Sacchettini, and J.W. Kelly Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis J. Med. Chem. 47 2004 355 374
36. N.S. Green, T.R. Foss, and J.W. Kelly Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis Proc. Natl. Acad. Sci. USA 102 2005 14545 14550
37. G. Ortore, and A. Martinelli Computational studies on transthyretin Curr. Med. Chem. 19 2012 2380 2387
38. C.E. Bulawa, S. Connelly, M. Devit, L. Wang, C. Weigel, J.A. Fleming, J. Packman, E.T. Powers, R.L. Wiseman, T.R. Foss, I.A. Wilson, J.W. Kelly, and R. Labaudiniere Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Proc. Natl. Acad. Sci. USA 109 2012 9629 9634
39. K.R. Chauhan, P.R. Kodavanti, and J.D. McKinney Assessing the role of ortho-substitution on polychlorinated biphenyl binding to transthyretin, a thyroxine transport protein Toxicol. Appl. Pharmacol. 162 2000 10 21
40. U. Rickenbacher, J.D. McKinney, S.J. Oatley, and C.C. Blake Structurally specific binding of halogenated biphenyls to thyroxine transport protein J. Med. Chem. 29 1986 641 648
41. K. Dhakal, X. He, H.J. Lehmler, L.M. Teesch, M.W. Duffel, and L.W. Robertson Identification of sulfated metabolites of 4-chlorobiphenyl (PCB3) in the serum and urine of male rats Chem. Res. Toxicol. 25 2012 2796 2804